statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioCardia ( NASDAQ:BCDA ) Full Year 2023 Results Key Financial Results Revenue: US$477.0k (down 65% from FY 2022). Net...

BioCardia Full Year 2023 Earnings: Misses Expectations

Q4 2023 BioCardia Inc Earnings Call Transcript

SUNNYVALE, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- BioCardia , Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...

BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results

BioCardia (NASDAQ:BCDA) publiera mercredi 27 mars son dernier rapport de r sultats. D chiffrez le rapport avec l'aide de Benzinga.
D finition de b n fices, r sultat net et BPA
Les b n fices et le BPA...

Aper u des b n fices : BioCardia

BioCardia (NASDAQ:BCDA) render noti i prossimi risultati degli utili mercoled 27 marzo. Ecco la guida di Benzinga con tutte le informazioni pi importanti per la pubblicazione degli utili.
Cosa...

Anteprima degli utili di BioCardia

El mi rcoles, 27 de marzo, BioCardia (NASDAQ:BCDA) publicar su ltimo informe de ganancias. El avance de Benzinga para BioCardia est incluido en el siguiente informe.
 Qu son ganancias, ingresos...

Un avance de las ganancias de BioCardia

SUNNYVALE, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- BioCardia , Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...

BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024

BioCardia and StemCardia partners for heart failure treatment candidate...

BioCardia and StemCardia partners for heart failure treatment candidate

Partnership targets heart failure, the leading cause of death and a condition with limited treatment optionsBioCardia's biotherapeutic delivery system with established safety profile enables...

BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

BioCardia announces CMS approval of coverage of CardiAMP Phase III study

BioCardia, Inc. is a clinical-stage biotherapeutic company. It engages in the business of developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. The company was founded on January 12, 1994 and is headquartered in Sunnyvale, CA.

Watchers	5,315
52-Wk Low	$0.32
52-Wk High	$2.92

Volume	65,484.00
52-Wk High	$2.92
52-Wk Low	$0.32

Period	Estimated	Reported	Surprise	Result
Q1'24	--	-$0.09	--	N/A
Q4'23	-$0.08	-$0.09	-20.00%	MISSED
Q3'23	-$0.12	-$0.12	--	EXPECTED
Q2'23	-$0.16	-$0.17	-8.51%	MISSED
Q1'23	-$0.16	-$0.17	-6.25%	MISSED

BCDA BioCardia Inc.

About

Feed

News

Earnings

Fundamentals